Sanofi Pasteur Vaxdesign Corporation

Vaxdesign Corporation

Virginia Commonwealth University

Sciperio, Inc

Massachusetts Institute of Technology

The Scripps Research Institute

Mount Sinai School of Medicine

Whitehead Institute for Biomedical Research

Nanopore, Inc.

Whitehead Institute

Sanofi Pasteur Vaxdesign Corp. Et Al.

New York University

William L Warren

Russell Higbee

Heather Fahlenkamp

Guzman Sanchez-Schmitz

Eric Mishkin

Donald Drake

Anatoly Kachurin

Conan Li

John G Tew

Robert Parkhill

Janice Moser

Haifeng Song

Inderpal Singh

Darrell J Irvine

Luis Mosquera

Mohey Eldin M El Shikh

Michael D Rivard

Gwendalyn J Randolph

Mike Nguyen

Bruce Torbett

Selva Sukumar

Kenneth H Church

Santosh Pawar

Nir Hacohen

Robert L Parkhill

Robert M Taylor

Michael N Nguyen

Robert L Stewart

David Moe

Anatoly M Kachurin

Nir Harcohen

Ayesha Mahmood

Douglas M Smith

Vladimir Pelekhaty

Vaughan Wittman

Mark Simpkins

Evan Gomes

Russel G Higbee

James S Dusenbury

Mark L Kargel

Brian K Hargrave

Anatoliy Kachurin

Tirumalai Kamala

Donald Drake Iii

Mohey Edin M El Shikh

Eric Mihkin

G Sanchez

Conan K N Li

Mohey Eldin El Shikh

Donald Iii Drake

Mohey Edin El Shikh

Russell G Higbee

Conan K Li

In vitro biomimetic models of the neonatal immune system are provided along with methods of using the models in pre-clinical assessment of infant immune cell-mediated and humoral responses to immunogenic stimulation, such as vaccination. The models include one comprising cord blood-derived T follicular helper cells and B cells, and one comprising cord blood-derived dendritic cells and CD4+ T cells. The models can be used, for example, to assess candidate vaccines via analysis of cellular responses to antigen and vaccine exposure.

In vitro neonatal biomimetic (nMIMIC) model and methods of using same

The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.

Artificial immune system: methods of use

The present invention comprises artificial tissue constructs that serve as in vitro models of mammalian lung tissue. The artificial tissue constructs of the present invention comprise functionally equivalent in vitro tissue scaffolds that enable immunophysiological function of the lung. The constructs can serve as novel platforms for the study of lung diseases (e.g., interstitial lung diseases, fibrosis, influenza, RSV) as well as smoke- and smoking-related diseases. The artificial tissue constructs of the present invention comprise the two components of alveolar tissue, epithelial and endothelial cell layers.

Artificial tissue constructs comprising alveolar cells and methods for using the same

The present invention relates to methods for preparing an artificial immune system. The artificial immune system comprises a cell culture comprising T cells, B cells and antigen-primed dendritic cells. The artificial immune system of the present invention can be used for in vitro testing of vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals.

Methods for testing an immune response using cultures of T cells, B cells, dendritic cells and follicular dendritic cells

Methods for testing an immune response using cultures of T cells, B cells and dendritic cells

The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.

Methods for assaying responses to vaccines

The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system.

Methods for antibody production

The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the tissues of the immune system in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates and other materials in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system, coupled with disease models to provide a more complete representation of an immune response.

Methods of evaluating a test agent in a diseased cell model

Artificial immune system: methods for making and use

Methods of evaluating an immune response to an antigen

The present invention relates to methods for preparing an artificial immune system. The artificial immune system comprises a cell culture comprising a three-dimensional matrix comprising lymphoid tissue, a three-dimensional matrix comprising epithelial and/or endothelial cells, and diseased cells. The artificial immune system of the present invention can be used for in vitro testing of vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals.

Disease model incorporation into an artificial immune system (AIS)

Method for determining the immunogenicity of an antigen

Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS)

Growing community of inventors

Orlanda, FL, United States of America

William L Warren